Sch 3ACT listed appendix D

Schedule 3 ACT listed appendix D medicines—standing (see s 31, s 41, s 160, s 591, s 592 and s 593) Part 3.1 Approval conditions 3.1 Definitions—sch 3 In this schedule: approved indication means an indication that is accepted by the Secretary of the Australian Government Department of Health in relation to the medicine in the Australian Register of Therapeutic Goods. Note Approved indications are shown in the public summary of the Australian Register of Therapeutic Goods on the Therapeutic Goods Administration website at www.tga.gov.au. condition 1, for a prescriber prescribing or supplying an ACT listed prescriber must ensure that the possibility of pregnancy by the woman has been excluded prior to commencement of treatment. condition 2, for a prescriber prescribing or supplying an ACT listed during, or for a period of 1 month after the completion of, treatment. condition 3, for a prescriber prescribing or supplying an ACT listed during, or for a period of 3 months after the completion of, treatment.

Approval conditions Part 3.1 Section 3.1 condition 4, for a prescriber prescribing or supplying an ACT listed during, or for a period of 24 months after the completion of,

Part 3.2 Standing approvals for ACT listed appendix D medicines Part 3.2 Standing approvals for ACT listed appendix D medicines item 1 specialist practising dermatology acitretin for human use alefacept for human use bexarotene for human use etretinate for human use isotretinoin for human oral use thalidomide for human use 2 specialist practising endocrinology, gynaecology or obstetrics clomiphene for human use corifollitropin alfa for human use cyclofenil for human use dinoprost for human use dinoprostone for human use follitropin alpha (recombinant human follicle-stimulating hormone) follitropin beta (recombinant human follicle-stimulating hormone) for human use follitropin delta (recombinant human follicle-stimulating hormone) for human use luteinising hormone for human use urofollitropin (human follicle-stimulating hormone)

Standing approvals for ACT listed appendix D medicines Part 3.2 item 3 specialist practising mental health doctor employed by Territory and working under supervision of chief psychiatrist under Mental Health Act clozapine for human use 4 specialist physician ambrisentan for human use acitretin for human use etretinate for human use bexarotene for human use bosentan for human use enzalutamide for human use isotretinoin for human oral use lenalidomide for human use macitentan for human use pomalidomide riociguat for human use sitaxentan for human use teriparatide for human use thalidomide for human use tretinoin for human oral use

Part 3.2 Standing approvals for ACT listed appendix D medicines item 5 specialist practising dentistry, dermatology, intensive care medicine, paediatrics and child health, physician, emergency hydroxychloroquine for initial treatment 6 prescriber hydroxychloroquine (a) for treatment initiated before commencement of the Poisons Standard Amendment (Hydroxychloroquine and Salbutamol) Instrument 2020 (Cwlth) (F2020L00291);or (b) for continuation of treatment initiated by a specialist under item 5 7 specialist practising dermatology, gastroenterology and hepatology, infectious diseases, paediatric gastroenterology and hepatology, paediatric infectious diseases ivermectin for initial treatment for an indication that is not an approved indication